<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076556</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01373</org_study_id>
    <secondary_id>NCI-2011-01373</secondary_id>
    <secondary_id>OSU 09089</secondary_id>
    <secondary_id>CDR0000666448</secondary_id>
    <secondary_id>OSU-09089</secondary_id>
    <secondary_id>OSU 09089</secondary_id>
    <secondary_id>8267</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT01076556</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and the best dose of alvocidib when given
      together with cyclophosphamide and rituximab in treating patients with high risk B-cell
      chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such
      as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
      killing the cells or by stopping them from dividing. Alvocidib may stop the growth of cancer
      cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
      rituximab, can also block cancer growth in different ways. Some block the ability of cancer
      cells to grow and spread. Other find cancer cells and help kill them or carry cancer-killing
      substances to them. Giving cyclophosphamide, alvocidib, and rituximab together may kill more
      cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the dose-limiting toxicity and maximum-tolerated dose of treatment with
      cyclophosphamide, alvocidib, and rituximab in patients with high-risk B-cell chronic
      lymphocytic leukemia or small lymphocytic lymphoma.

      II. To determine the feasibility of administering this regimen as an outpatient regimen in
      these patients.

      SECONDARY OBJECTIVES:

      I. To determine the complete response rate, partial response rate, and minimal-residual
      disease-negative response rate in patients treated with this regimen.

      II. To determine the pharmacokinetics of alvocidib and dexamethasone as part of this regimen.

      III. To determine the immunologic effects of this regimen as measured by serial T-cell and
      NK-cell number, T-cell function, and immunoglobulin levels.

      OUTLINE: This is a dose-escalation study of alvocidib.

      Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide
      IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8
      only in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease
      progression or unacceptable toxicity. Blood samples are collected periodically for
      pharmacokinetic and pharmacodynamic studies.

      After completion of study treatment, patients are followed up for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of combination therapy with Cyclophosphamide, Alvocidib, and Rituximab</measure>
    <time_frame>21 days</time_frame>
    <description>Determined using the CTEP Active Version of the CTCAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related adverse events assessed using the CTEP Active Version of the CTCAE</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Small Lymphocytic Lymphoma</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvocidib Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
    <other_name>4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis-</other_name>
    <other_name>Flavopiridol Hydrochloride</other_name>
    <other_name>HL-275</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-86-8275</other_name>
    <other_name>L-868275</other_name>
    <other_name>MDL 107,826A</other_name>
    <other_name>MDL-107826A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab, cyclophosphamide, alvocidib)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed chronic lymphocytic leukemia (CLL) or B-cell prolymphocytic
             leukemia* (PLL) arising from CLL

               -  Patients must have documented B-cell lymphocytosis &gt; 5 x 10^9/L at some point
                  since initial diagnosis of CLL

               -  Patients must have B-cells that co-express CD5 with CD19 or CD20

               -  Patients who do not have dim sIg or CD23 expression on their leukemia cells
                  should be examined for cyclin D1 over-expression or t(11;14) to rule out mantle
                  cell lymphoma

          -  To be considered high risk, patients must meet the following criteria:

               -  At least 1 of the following:

                    -  17p deletion

                    -  11q deletion

                    -  Un-mutated IgV_H (≥ 98% homology)

                    -  Age &gt; 70 years

                    -  B_2M &gt; 4

               -  AND at least 1 of the following:

                    -  Progressive or marked splenomegaly and/or lymphadenopathy

                    -  Anemia (hemoglobin &lt; 11 g/dL) or thrombocytopenia (platelets &lt; 100,000/mm^3)

                    -  Weight loss exceeding 10% of body weight over preceding 6 months

                    -  NCI grade 2 or 3 fatigue

                    -  Fevers &gt; 100.5° F or night sweats for &gt; 2 weeks without evidence of
                       infection

                    -  Progressive lymphocytosis, with an increase exceeding 50% over a 2-month
                       period or a doubling time of &lt; 6 months

          -  No other concurrent hormones, chemotherapy, or radiotherapy except for steroids for
             new adrenal failure or hormones for nondisease-related conditions (e.g., insulin for
             diabetes)

               -  No requirement for chronic corticosteroids

          -  ECOG performance status 0-2

          -  Creatinine ≤ 2.0 mg/dL

          -  Bilirubin ≤ 1.5 times normal unless due to Gilbert disease, hemolysis, or disease
             infiltration of the liver

          -  AST ≤ 2 times normal unless due to hemolysis or disease infiltration of the liver

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No secondary or other malignancy that will limit survival to &lt; 2 years

          -  No uncontrolled concurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situations that would limit compliance with study
                  requirements

          -  No uncompensated HIV without adequate CD4 (&gt; 200/mm^3) and requiring HIV medication

          -  No active hepatitis B infection

          -  No known G6PD deficiency

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to alvocidib, cyclophosphamide, rituximab, or other agents used
             in this study

          -  No prior alvocidib

          -  No prior purine analog therapy

          -  No more than 1 prior treatment with a biologic or alkylating agent

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Flynn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

